pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›OLANZAPINE
drug · small molecule
save

OLANZAPINE

Phase 1updated 3mo ago
by $RDY DR REDDYS LABORATORIES LTD🔗 ChEMBL
Phase 1
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval872 co-mentions · 299 sources
  • drugLYBALVI718 co-mentions · 300 sources
  • drugolanzapine ER711 co-mentions · 300 sources
  • drugolanzapine ODT437 co-mentions · 300 sources
  • tagSmall Molecule318 co-mentions · 239 sources
  • drugOLANZAPINE AND FLUOXETINE HYDROCHLORIDE180 co-mentions · 60 sources
  • drugProzac120 co-mentions · 60 sources
  • drugolanzapine pamoate XR120 co-mentions · 30 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 27 investigational indications.

targets

D2-like dopamine receptor5-hydroxytryptamine receptor 2C5-hydroxytryptamine receptor 2A

all catalysts(0)

nothing on the calendar yet

Trials studying OLANZAPINE

  • phase3Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medicationsrecruitingn=380
  • phase3Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorderrecruitingn=220
  • phase1Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disordercompletedn=106
  • phase1An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophreniacompletedn=153
  • —A Study of Olanzapine in Participants With Bipolar Disorder.recruitingn=3,000
  • phase1Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidonecompletedn=81
  • phase1Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophreniacompletedn=24
  • phase3A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniformcompletedn=337
more trials →

News(1)

  • As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
    Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…
    biospace · 5d ago
brand
OLANZAPINE
trade names
Arkolamyl, Olansek, Olanzapine, Olanzapine apotex, Olanzapine cipla (previously olanzapine neopharma), Olanzapine component of lybalvi
generic
OLANZAPINE
MOA
12.1 Mechanism of Action The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT2) antagonism.
indication
1 INDICATIONS AND USAGE Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As Olanzapine and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. ( 1.5 ) Efficacy was established with Symbyax (olanzapine and fluoxetine in combination); refer to the product label for Symbyax. Treatment of treatment resistant depression. ( 1.6
phase
phase_1
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?